海湾扇贝多肽对小鼠H_(22)肝癌移植瘤的抑制机制研究  

Mechanism of Inhibition by Polypeptide from Bay Scallop of H_(22) Hepatocarcinoma Transplanted into Mice

作　　者：刘媛[1,2] 王健[2] 牟建楼[1] 刘亚琼[1] 孙剑锋[1] 王颉[1] 

机构地区：[1]河北农业大学食品科技学院,河北保定071000 [2]河北北方学院食品科学系,河北张家口075000

出　　处：《现代食品科技》2014年第12期1-6,共6页Modern Food Science and Technology

基　　金：国家海洋公益性行业科研专项(201205031);河北省科技计划项目(14273205D)

摘　　要：探讨海湾扇贝多肽(polypeptide from bay scallop,PBS)对小鼠H22肝癌移植瘤的抑瘤作用及机制。将50只KM小鼠随机分为正常对照组、H22肝癌模型组和PBS低、中、高剂量组共5组,按试验设计进行体内灌胃试验。结果显示,低、中、高剂量组的抑瘤率分别为28.16%、41.93%和84.00%,具有量效依赖趋势。与模型组相比,三剂量组小鼠血清中突变型p53、Survivin、8-iso-PGF2α和MDA的水平均有所降低,而IL-2、GSH-Px、SOD和TNF-α的水平均有所升高,且中剂量组较其他两组效果更明显;三剂量组小鼠肝脏组织提取液呈现相同变化趋势。肿瘤组织病理学观察也表明PBS有较好的抗肿瘤生物学效应。PBS对小鼠肝癌H22细胞具有明显的抑制作用。The aim of this study was to explore the inhibitory effect and the underlying mechanism of inhibition by polypeptide from bay scallop （PBS） on H22 hepatocarcinoma transplanted in mice. A total of 50 Kunming （KM） mice were randomly divided into normal control group, H22 hepatocarcinoma model group, low-dose PBS （500 mg/kg.bw） group, medium-dose PBS （1000 mg/kg·bw） group, and high-dose PBS （1500 mg/kg·bw） group. An in vivo gavage experiment was performed. The results showed that the tumor inhibition rate in low-, medium-, and high-dose groups were 28.16%, 41.93%, and 84.00%, respectively, showing a dose-dependent effect. Compared to the model group, serum levels of mutant p53, survivin, 8-iso-prostaglandin F2α （PGF2α）, and malondialdehyde （MDA） in the three PBS groups showed a decrease, while that of interleukin-2, glutathione peroxidase （GSH-Px）, superoxide dismutase （SOD）, and tumor necrosis factor-u showed an increase. Additionally, the effect seen in the medium-dose group was more obvious than that in the other two groups. The same trend was found in the liver extracts from the three dose groups. Pathological evaluations also showed visible antitumor effects by PBS. Thus, this study indicated that PBS exerts obvious inhibitory effects on mouse H22 hepatocarcinoma cells.

关 键 词：海湾扇贝多肽 H22荷瘤小鼠 肿瘤抑制率 p53蛋白 SURVIVIN蛋白 

分 类 号：R285.5[医药卫生—中药学] TS254.5[医药卫生—中医学]